BR112019007028A2 - métodos e composições farmacêuticas para o tratamento do câncer renal - Google Patents
métodos e composições farmacêuticas para o tratamento do câncer renalInfo
- Publication number
- BR112019007028A2 BR112019007028A2 BR112019007028A BR112019007028A BR112019007028A2 BR 112019007028 A2 BR112019007028 A2 BR 112019007028A2 BR 112019007028 A BR112019007028 A BR 112019007028A BR 112019007028 A BR112019007028 A BR 112019007028A BR 112019007028 A2 BR112019007028 A2 BR 112019007028A2
- Authority
- BR
- Brazil
- Prior art keywords
- kidney cancer
- compositions
- treatment
- pharmaceutical methods
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
a presente invenção se refere a métodos e composições farmacêuticas para o tratamento de câncer renal. os inventores mostraram que enquanto a elabela (ela) é expressa principalmente no rim, sua expressão é reduzida no câncer renal humano. em um modelo animal de xenoenxerto (injeção subcutânea ou subcapsular), ela inibe a progressão do tumor. em particular, a presente invenção se refere a um método para tratar câncer renal num indivíduo com necessidade do mesmo compreendendo administrar ao indivíduo uma quantidade terapeuticamente eficaz de um polipeptídeo ela compreendendo uma sequência de aminoácidos possuindo pelo menos 90% de identidade com a seq id no: 1 (qrpvnltmrrklrkhnclqrrcmplhsrvpfp), em que o resíduo de arginina (r) na posição 9, 10, 20 ou 21 é opcionalmente mutado.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306312 | 2016-10-05 | ||
| EP17305507 | 2017-05-04 | ||
| PCT/EP2017/075134 WO2018065440A1 (en) | 2016-10-05 | 2017-10-04 | Methods and pharmaceutical compositions for the treatment of kidney cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019007028A2 true BR112019007028A2 (pt) | 2019-10-01 |
Family
ID=60138344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019007028A BR112019007028A2 (pt) | 2016-10-05 | 2017-10-04 | métodos e composições farmacêuticas para o tratamento do câncer renal |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11052131B2 (pt) |
| EP (1) | EP3522985B1 (pt) |
| JP (1) | JP2019530705A (pt) |
| CN (1) | CN110072593A (pt) |
| AU (1) | AU2017340954A1 (pt) |
| BR (1) | BR112019007028A2 (pt) |
| CA (1) | CA3039103A1 (pt) |
| DK (1) | DK3522985T3 (pt) |
| ES (1) | ES2907741T3 (pt) |
| IL (1) | IL265824A (pt) |
| RU (1) | RU2752322C2 (pt) |
| WO (1) | WO2018065440A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110960671A (zh) * | 2019-12-25 | 2020-04-07 | 广州中医药大学(广州中医药研究院) | Elabela多肽新用途及其药物 |
| CN112210001A (zh) * | 2020-10-25 | 2021-01-12 | 兰州大学 | 多肽片段ela13及其用途 |
| CN116655773B (zh) * | 2022-11-07 | 2023-12-22 | 吉林大学第一医院 | 一种肽类激素Elabela突变体及其在心肾综合征中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| RU2188026C1 (ru) * | 2001-01-12 | 2002-08-27 | Ростовский научно-исследовательский онкологический институт | Способ лечения рака почки |
| US9309314B2 (en) * | 2013-12-03 | 2016-04-12 | Agency For Science, Technology And Research (A*Star) | Polypeptides, nucleic acids and uses thereof |
| EP3206707B1 (en) * | 2014-10-13 | 2020-12-02 | University of Maryland, Baltimore | Fc-ela-32 and its use in the treatment of cardiac conditions |
-
2017
- 2017-10-04 DK DK17786848.6T patent/DK3522985T3/da active
- 2017-10-04 EP EP17786848.6A patent/EP3522985B1/en active Active
- 2017-10-04 AU AU2017340954A patent/AU2017340954A1/en not_active Abandoned
- 2017-10-04 US US16/339,931 patent/US11052131B2/en active Active
- 2017-10-04 CA CA3039103A patent/CA3039103A1/en not_active Abandoned
- 2017-10-04 BR BR112019007028A patent/BR112019007028A2/pt not_active Application Discontinuation
- 2017-10-04 JP JP2019518545A patent/JP2019530705A/ja not_active Ceased
- 2017-10-04 ES ES17786848T patent/ES2907741T3/es active Active
- 2017-10-04 WO PCT/EP2017/075134 patent/WO2018065440A1/en unknown
- 2017-10-04 RU RU2019112479A patent/RU2752322C2/ru active
- 2017-10-04 CN CN201780067931.5A patent/CN110072593A/zh active Pending
-
2019
- 2019-04-04 IL IL265824A patent/IL265824A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019112479A (ru) | 2020-11-06 |
| CA3039103A1 (en) | 2018-04-12 |
| RU2752322C2 (ru) | 2021-07-26 |
| WO2018065440A1 (en) | 2018-04-12 |
| JP2019530705A (ja) | 2019-10-24 |
| AU2017340954A1 (en) | 2019-05-02 |
| CN110072593A (zh) | 2019-07-30 |
| IL265824A (en) | 2019-06-30 |
| DK3522985T3 (da) | 2022-02-14 |
| EP3522985B1 (en) | 2021-12-01 |
| US11052131B2 (en) | 2021-07-06 |
| EP3522985A1 (en) | 2019-08-14 |
| US20200030413A1 (en) | 2020-01-30 |
| RU2019112479A3 (pt) | 2021-01-27 |
| ES2907741T3 (es) | 2022-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501414A1 (en) | Amino acid compositions and methods for the treatment of liver diseases | |
| BR112017023269A2 (pt) | métodos para tratamento de câncer | |
| MX2019010459A (es) | Vacuna. | |
| MX2021002543A (es) | Proceso para la preparacion de composiciones de vacunas. | |
| MX2022010270A (es) | Nuevo enfoque para tratar el cancer mediante el uso de la inmunomodulacion. | |
| PH12019500965A1 (en) | Crenolab for treating flt3 mutated proliferative disorders associated mutations | |
| EA201791199A1 (ru) | Способ лечения болезни альцгеймера | |
| PH12017500444A1 (en) | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia | |
| PH12017500032A1 (en) | Improved a� protofibril binding antibodies | |
| RU2017116973A (ru) | Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса | |
| BR112019007028A2 (pt) | métodos e composições farmacêuticas para o tratamento do câncer renal | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| EA201691789A1 (ru) | Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты | |
| EA201990298A1 (ru) | Способы и композиции для лечения рака | |
| EA201890815A1 (ru) | Аминокислотные композиции с модифицированным высвобождением для перорального введения | |
| BR112018072681A2 (pt) | anticorpos anti-il-1r3 humanizados | |
| BR112017013300A2 (pt) | alfa galactosidase a recombinante e/ou fragmento de alfa galactosidase a recombinante biologicamente ativo, composição, sequência de polinucleotídeos recombinantes, vetor de expressão, célula hospedeira, métodos para produzir uma variante de alfa galactosidase a e para tratar e/ou prevenir os sintomas da doença de fabry, composição farmacêutica, e, uso das composições. | |
| MX2019003970A (es) | Péptidos de arginasa inmunogénicos. | |
| EA202190310A1 (ru) | Белок для лечения воспалительных заболеваний | |
| MY194448A (en) | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis | |
| ZA202001568B (en) | Methods and compositions for treating chronic lung diseases | |
| BR112019005513A2 (pt) | composição imunogênica, molécula de ácido nucleico, peptídeo, e, métodos para induzir uma resposta imune contra proteína de ativação de fibroblasto e para tratar ou prevenir uma patologia associada a tumor. | |
| MX2020001217A (es) | Metodos de tratamiento de sintomas de gastroparesia usando velusetrag. | |
| EA201991502A1 (ru) | Композиции на основе аминокислот и способы лечения заболеваний печени | |
| BR112015023697A2 (pt) | inibidores de ácidos biliares de reciclagem para tratamento de esôfago de barrett e doença do refluxo gastroesofágico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |